Principal Investigator: Ms Reno Leeming
Dartmouth College, USATags: 53618, bladder, cancer, mortality, polymorphisms, SNPs, survival
Despite recent therapeutic advancements, urinary bladder cancer remains the most expensive cancer to treat. Previous studies have discovered germline genetic variants that increase risk for urinary bladder cancer, however little is known about whether these variants are related to survival time after a diagnosis of bladder cancer. Here, we propose to use the genome-wide genotyping data of individuals diagnosed with urinary bladder cancer in the UK Biobank to validate results from a genetic association study of bladder cancer-specific and overall survival conducted in the New England region of the United States. These findings may prompt future studies that help improve therapeutic decisions in the clinical setting.